ERBB2 and breast carcinoma: Nowadays, the available treatments for HER2-positive breast cancer includes anti-HER2 agents targeting the HER2 family intracellularly or extracellularly, such as trastuzumab, lapatinib, pertuzumab, trastuzumab emtansine, and neratinib (1).